Boltz

๐Ÿ“‚ Artificial Intelligence๐Ÿ“‚ Healthtech๐Ÿ“ London๐Ÿ—“๏ธ Founded: 2025

Biomolecular AI company founded by MIT researchers and now based in London, building models to design molecules and proteins.

Europe's most interesting startup stories. Every week.

No spam. Unsubscribe anytime.

Podcast Episode

๐ŸŽ™๏ธ Deep Dive

Boltz, Mistral AI, Elysian Aircraft โ€” capital for drug discovery, sovereign AI and electric aviation โ€” Daily News November 19, 2026

Listen to the episode

About Boltz

Boltz is a public benefit company founded in 2025 by Gabriele Corso (CEO), Jeremy Wohlwend and Saro Passaro, MIT researchers known for open-source biomolecular structure prediction models. Started in the United States, it is now based in London's King's Cross, where about 40 researchers and engineers work. It develops the BoltzMol-1 and BoltzProt-1 models, available via API, and the Boltz Lab platform for scientists and AI agents; it reports signed partnerships with six of the world's 20 largest pharma companies, including Pfizer, GSK, Takeda and Bristol Myers Squibb, and 50-fold growth in molecular token volume among paying customers since June. After a $28 million seed round in January 2026, on 18 November 2026 it announced a $110 million Series A led by Bessemer Venture Partners, with Andreessen Horowitz, Amplify Partners, Zetta Venture Partners and Obvious Ventures returning and Greycroft, F-Prime Capital, Hummingbird and Benchling joining. The money will go into compute, data and hiring. Nvidia also announced an investment in 2026, with no amount disclosed.

The Story

Founded in 2025 by three MIT researchers, Gabriele Corso, Jeremy Wohlwend and Saro Passaro, and later relocated to London.

How Boltz works

Business Model

Partnerships with pharma companies and paid access to models and platform.

Revenue Model

Partnerships and access to the platform and models.

Products & Services

Key Products

  • BoltzMol-1
  • BoltzProt-1
  • Boltz Lab

Core Use Cases

  • Small-molecule design
  • Protein design
  • Biomolecular structure prediction

Market & Clients

Key Customers

Large pharma companies, biotechs and research labs.

Geographic Presence

GB

How Boltz competes

Competitive Advantages

  • Open-source models widely adopted by the scientific community
  • Partnerships with major pharma groups

How Boltz grows

Growth Strategy

Invest in compute and data, meet partner demand and expand the team.

Distribution Model

API, the Boltz Lab platform and direct partnerships.

Key Risks

  • Competition in AI drug discovery
  • Experimental validation of model outputs
  • Compute costs

Strategic Insights

  • Its open-source origins built a user community before commercialisation.
  • The move to London brings one of the emerging AI-for-biology companies to Europe.

Funding & Investors

Total Funding

138000000

Funding Rounds

  • 2026 - Series A: $110M
    Lead: Bessemer Venture Partners
  • 2026 - Seed: $28M

Key Investors

Bessemer Venture PartnersAndreessen HorowitzAmplify PartnersZetta Venture PartnersObvious VenturesGreycroftF-Prime CapitalHummingbirdBenchlingNvidia

Founding Team

Founders

Gabriele CorsoCo-founder & CEO
Jeremy WohlwendCo-founder
Saro PassaroCo-founder

Key Metrics

Partnership con le 20 maggiori aziende farmaceutiche6 (2026)
Crescita del volume di token molecolari dei clienti paganti50 volte da giugno 2026 (2026)
Teamcirca 40 persone (2026)

Lessons from Boltz

  • Releasing open-source models can speed up adoption and open the door to commercial partnerships with large customers.

Similar Startups

๐Ÿ“ London

Isomorphic Labs

Isomorphic Labs applies advanced AI models โ€” including those underlying AlphaFold โ€” to drug discovery and design, aiming to transform molecular biology into a computational process and radically accelerate therapeutic pipelines.

Read Analysis
๐Ÿ“ London

Babylon Health

Company born in London in 2013 with digital doctor consultations and AI tools for patients. A unicorn in 2019, listed on the NYSE in 2021, assets sold to eMed in 2023.

Read Analysis
๐Ÿ“ London

Frontier Health

London healthtech developing Juno, an AI agent supporting hospital administrative staff.

Read Analysis

Sources

๐ŸŽ™๏ธ Scalable Podcast โ€” European startup stories ยท ๐Ÿ‡ฎ๐Ÿ‡น in Italian
Spotify ๐ŸŽง Apple